Journal: BMC Musculoskeletal Disorders
Article Title: Knockdown of CLEC4D alleviates myoblast dysfunction and inflammation in sarcopenia by inhibiting the JAK/STAT pathway
doi: 10.1186/s12891-025-09085-x
Figure Lengend Snippet: Silencing CLEC4D attenuates D-gal-induced myoblast dysfunction and inflammation via inhibiting the JAK/STAT pathway. ( A ) CCK-8 assay measuring cell viability. ( B ) Flow cytometry analysis of apoptosis levels. ( C ) SA-β-gal staining (Magnification: 200×, Scale bar: 100 μm). ( D ) RT-qPCR analysis of the mRNA expression of myogenic markers. ( E ) RT-qPCR analysis of the mRNA expression of muscle atrophy markers. ( F ) Western blot detection of proteins related to myoblast differentiation. ( G ) Western blot analysis of muscle atrophy marker expression. ( H ) ELISA for detecting inflammatory factors in cells. ** P < 0.01 vs. Control group, ## P < 0.01 vs. D-gal + LV-shNC group, $$ P < 0.01 vs. D-gal + LV-shCLEC4D group
Article Snippet: Additionally, the JAK/STAT pathway was activated by treating cells with the JAK/STAT activator RO8191 (2 μM; MedChemExpress, New Jersey, USA) for 24 h.
Techniques: CCK-8 Assay, Flow Cytometry, Staining, Quantitative RT-PCR, Expressing, Western Blot, Marker, Enzyme-linked Immunosorbent Assay, Control